We report a case of a 75-year-old man with concomitant metastatic prostate cancer and progressive follicular lymphoma and the utility of molecular imaging in differentiating these 2 conditions. 18F-FDG PET/CT can offer accurate staging in many cancers, although its role in prostate cancer is limited. The role of 18F-DCFPyL (PSMA) PET/CT in prostate cancer is evolving and has been demonstrated to have a higher sensitivity than conventional bone scan and CT scan. Together, FDG and PSMA PET/CT studies may offer a noninvasive approach to individually characterize concomitant malignancies, aiding optimization of management and follow-up.
From the *Department of Nuclear Medicine, Prince of Wales Hospital, Randwick
†Faculty of Medicine, University of New South Wales, Sydney
Departments of ‡Oncology
§Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Received for publication February 12, 2019; revision accepted June 2, 2019.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Nattakorn Dhiantravan, MBBS, MBA, Department of Nuclear Medicine, Prince of Wales Hospital, 320-346 Barker St, Randwick NSW 2031. E-mail: email@example.com.
Online date: July 25, 2019